三种短疗程抗生素方案与单剂磷霉素治疗女性非复杂性下尿路感染的临床与细菌学疗效(SCOUT):一项实用性、多中心、开放标签、随机临床试验
SCOUT试验在西班牙初级保健中心纳入768例有UTI症状且尿试纸阳性的女性,随机分配至单剂磷霉素、两剂磷霉素、呋喃妥因5天或匹美西林3天方案。第7天临床缓解率单剂磷霉素最低(59%),呋喃妥因最高(74%),差异有统计学意义;不良事件多为轻度自限性。
要点
- 呋喃妥因5天方案第7天临床缓解率最高(74%),单剂磷霉素最低(59%)。
- 不良事件多为轻度自限性,以胃肠道反应为主,严重不良事件4例。
核心结论
- 呋喃妥因是治疗非复杂性UTI最有效的方案,单剂磷霉素效果最差,应重新评估磷霉素作为一线抗生素的地位。
研究设计与样本
- 4期实用性、多中心、平行组、开放标签、随机临床试验,2022至2024年在西班牙初级保健中心开展。
- 768例18岁以上有至少一项UTI特异性症状且尿试纸亚硝酸盐或白细胞酯酶阳性的女性,按1:1:1:1随机分配至四组。
- 四组方案:单剂磷霉素3g、两剂磷霉素3g、呋喃妥因100mg每日三次共5天、匹美西林400mg每日三次共3天。
- 主要结局为第7天临床缓解(所有感染症状消失)的比例。
主要发现
- 纳入主要分析的720例中,单剂磷霉素组临床缓解109/185(59%),呋喃妥因组128/172(74%),匹美西林组127/182(70%),两剂磷霉素组122/181(67%)。
关键数值与推荐
- 临床缓解定义为第7天所有感染症状消失。
- 严重不良事件4例,其中1例与研究治疗相关(匹美西林组肾盂肾炎1例)。
临床怎么用
- 对于有UTI症状且尿试纸阳性的女性,呋喃妥因5天方案可作为优先选择之一。
- 单剂磷霉素的临床缓解率较低,不宜作为首选经验性治疗。
- 两剂磷霉素与匹美西林3天方案疗效居中,可根据具体情况选用。
局限性
- 开放标签设计,医生和患者均未设盲,可能影响结局评估。
- 未收集种族和族裔数据。
- 主要分析仅纳入720例有可用数据的患者,排除48例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most guidelines recommend nitrofurantoin, fosfomycin, and sometimes pivmecillinam for uncomplicated urinary tract infections (UTIs), but direct comparisons between these antibiotics are needed. This study evaluated the effectiveness and safety of a single dose of fosfomycin compared with two doses of fosfomycin and short-course regimens of nitrofurantoin and pivmecillinam in women with UTI symptoms. METHODS: This phase 4, pragmatic, multicentre, parallel-group, open-label, randomised clinical trial was conducted in Spanish primary care centres from 2022 to 2024. Women aged 18 years or older with at least one UTI-specific symptom (dysuria, urinary urgency, urinary frequency, or suprapubic tenderness) and a positive urine dipstick test for either nitrites or leukocyte esterase were randomly assigned (1:1:1:1) to one of four treatments: a single 3 g dose of fosfomycin, two 3 g doses of fosfomycin, nitrofurantoin (100 mg three times per day for 5 days), or pivmecillinam (400 mg three times per day for 3 days). Doctors and patients were not masked to group assignment. The primary outcome was the proportion of patients with clinical resolution (defined as the disappearance of all infection symptoms) at day 7. This trial is registered with ClinicalTrials.gov (NCT04959331) and EudraCT (2021-001332-26) and is completed. FINDINGS: Of the 804 patients assessed for eligibility between April 4, 2022 and Nov 14, 2024, 768 patients were randomly allocated (191 to the single-dose fosfomycin group, 194 to the two-dose fosfomycin group, 190 to the nitrofurantoin group, and 193 to the pivmecillinam group). Patients had a median age of 48 years (IQR 34-63). Race and ethnicity data were not collected. Among the 720 women with available data included in the primary analysis, single-dose fosfomycin had the lowest proportion of clinical resolution (109 [59%] of 185 patients), while nitrofurantoin had the highest (128 [74%] of 172 patients; difference 15·5 percentage points [95% CI 5·9 to 25·1] vs single-dose fosfomycin; p=0·0168), followed by pivmecillinam (127 [70%] of 182; difference 10·9 percentage points [1·1 to 20·6]; p=0·2352) and the two-dose fosfomycin group (122 [67%] of 181; difference 8·5 percentage points [-1·4 to 18·3]; p=0·6935). Adverse events occurred in 38 (19·9% [95% CI 14·9 to 26·1) of 191 patients who received single-dose fosfomycin, 51 (26·3% [20·6 to 32·9]) of 194 who received two-dose fosfomycin, 51 (26·8% [21·0 to 33·6]) of 190 who received nitrofurantoin, and 41 (21·2% [16·1 to 27·5]) of 193 who received pivmecillinam. Most adverse events were mild and self-limiting, primarily gastrointestinal. Four serious adverse events occurred, of which one was related to the study treatment (one case of pyelonephritis in the pivmecillinam group). INTERPRETATION: Nitrofurantoin was the most effective treatment and single-dose fosfomycin the least effective treatment for UTIs. Adverse events were mild. The role of fosfomycin as a first-line antibiotic for uncomplicated UTI should be re-evaluated. FUNDING: Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund.
引用
- Llor C, Monfà R, Garcia-Sangenís A, et al. Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial. Lancet. 2026. PMID: 42026010. doi:10.1016/S0140-6736(25)02171-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。